This offer is only valid for patients with commercial insurance. Commercially insured patients whose insurance does not cover TARGRETIN will pay more. These savings offers are not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare, (including Medicare Advantage and Part A, B and D Plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. Void where prohibited by law, taxed or restricted. Cannot be redeemed at government-subsidized clinics. Valeant Pharmaceuticals reserves the right to rescind, revoke, or amend this offer without notice. You agree not to seek reimbursement for all or any part of the benefit received through this offer and are responsible for making any required reports of your use of this offer to any insurer or other third party who pays any part of the prescription filled. This offer is not valid for any person that is 65 years of age or older without commercial insurance. You must be 18 years of age or older to redeem this offer for yourself or a minor. You must present this coupon along with your prescription to participate in this program. You must activate this coupon before using by calling 1-888-201-1385 or visiting . Reimbursement limitations apply. Patient is responsible for all additional costs and expenses after reimbursement limits are reached. This coupon and offer are not health insurance.
DLBCL patients are at higher risk when they relapse early after R-CHOP chemotherapy and have a poor response to second-line rituximab-containing treatments even when these regimens involve high-dose therapy and autologous stem cell transplant.  Approximately half of DLBCL patients develop CHOP-resistant cells. A study of DLBCL cell lines indicated that 14-3-3ζ proteins may play a role in mediating resistance of DLBCL cells to CHOP. 14-3-3 proteins exert anti-apoptotic activity by interfering with the function of BH3-only proteins and has been validated as a potential molecular target for anticancer therapeutic development in other types of cancers.